MX2013008012A - Tratamiento para la lipodistrofia. - Google Patents

Tratamiento para la lipodistrofia.

Info

Publication number
MX2013008012A
MX2013008012A MX2013008012A MX2013008012A MX2013008012A MX 2013008012 A MX2013008012 A MX 2013008012A MX 2013008012 A MX2013008012 A MX 2013008012A MX 2013008012 A MX2013008012 A MX 2013008012A MX 2013008012 A MX2013008012 A MX 2013008012A
Authority
MX
Mexico
Prior art keywords
hiv
treatment
lipodystrophy
lipohypertrophy
lipoatrophy
Prior art date
Application number
MX2013008012A
Other languages
English (en)
Other versions
MX350611B (es
Inventor
Dhiraj Gambhire
Rajendrakumar Hariprasad Jani
Bipin Pandey
Kaushik Sata
Himanshu Kothari
Pankaj Ramanbhai Patel
Original Assignee
Cadila Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadila Healthcare Ltd filed Critical Cadila Healthcare Ltd
Publication of MX2013008012A publication Critical patent/MX2013008012A/es
Publication of MX350611B publication Critical patent/MX350611B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/333—Radicals substituted by oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Inorganic Chemistry (AREA)
  • Saccharide Compounds (AREA)
  • Biophysics (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Ceramic Products (AREA)

Abstract

La presente invención proporciona un compuesto terapéutico de fórmula (I) y sus sales farmacéuticamente aceptables, para la prevención y tratamiento de la lipodistrofia causada debido a la infección con VIH o terapia de combinación de los inhibidores de la proteasa (PI) del VIH-1 y/o los inhibidores de la transcriptasa inversa (nRTI), neutralizando la lipohipertrofia, lipoatrofia y anormalidades metabólicas en pacientes con VIH.
MX2013008012A 2011-01-31 2012-01-30 Tratamiento para la lipodistrofia. MX350611B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN257MU2011 2011-01-31
PCT/IN2012/000069 WO2012104869A1 (en) 2011-01-31 2012-01-30 Treatment for lipodystrophy

Publications (2)

Publication Number Publication Date
MX2013008012A true MX2013008012A (es) 2013-08-21
MX350611B MX350611B (es) 2017-09-11

Family

ID=54192841

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013008012A MX350611B (es) 2011-01-31 2012-01-30 Tratamiento para la lipodistrofia.

Country Status (29)

Country Link
US (3) US10017470B2 (es)
EP (2) EP3009136A1 (es)
JP (2) JP2014504610A (es)
KR (3) KR101633720B1 (es)
CN (2) CN103354757A (es)
AP (1) AP3920A (es)
AU (2) AU2012212992B2 (es)
BR (1) BR112013019352A2 (es)
CA (1) CA2825456C (es)
CL (1) CL2013002166A1 (es)
CO (1) CO6781497A2 (es)
CY (1) CY1117564T1 (es)
DK (1) DK2670486T3 (es)
EA (1) EA025421B1 (es)
ES (1) ES2569248T3 (es)
HR (1) HRP20160403T1 (es)
HU (1) HUE027512T2 (es)
IL (2) IL227266B (es)
ME (1) ME02392B (es)
MX (1) MX350611B (es)
MY (1) MY191100A (es)
NZ (1) NZ612804A (es)
PL (1) PL2670486T3 (es)
RS (1) RS54735B1 (es)
SG (1) SG191772A1 (es)
SI (1) SI2670486T1 (es)
SM (1) SMT201600129B (es)
UA (1) UA110813C2 (es)
WO (1) WO2012104869A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA110813C2 (uk) 2011-01-31 2016-02-25 Каділа Хелткере Лімітед Лікування ліподистрофії
US9171343B1 (en) 2012-09-11 2015-10-27 Aseko, Inc. Means and method for improved glycemic control for diabetic patients
US9897565B1 (en) 2012-09-11 2018-02-20 Aseko, Inc. System and method for optimizing insulin dosages for diabetic subjects
EP2988736A1 (en) * 2013-04-22 2016-03-02 Cadila Healthcare Limited A novel composition for nonalcoholic fatty liver disease (nafld)
EP3004053B1 (en) 2013-05-30 2021-03-24 Cadila Healthcare Limited A process for preparation of pyrroles having hypolipidemic hypocholesteremic activities
TW201636015A (zh) * 2013-07-05 2016-10-16 卡地拉保健有限公司 協同性組成物
IN2013MU02470A (es) 2013-07-25 2015-06-26 Cadila Healthcare Ltd
WO2015029066A1 (en) 2013-08-29 2015-03-05 Cadila Healthcare Limited Polymorphic form of pyrrole derivative and intermediate thereof
WO2015033357A2 (en) 2013-09-06 2015-03-12 Cadila Healthcare Limited An improved process for the preparation of pyrrole derivatives
US9233204B2 (en) 2014-01-31 2016-01-12 Aseko, Inc. Insulin management
US9486580B2 (en) 2014-01-31 2016-11-08 Aseko, Inc. Insulin management
EP3050023B1 (en) 2014-10-27 2021-08-25 Aseko, Inc. Subcutaneous outpatient management
US11081226B2 (en) 2014-10-27 2021-08-03 Aseko, Inc. Method and controller for administering recommended insulin dosages to a patient
JP2018511555A (ja) * 2015-02-27 2018-04-26 アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． リポジストロフィー集団におけるアポリポタンパク質Ｃ−ＩＩＩ（ＡｐｏＣＩＩＩ）発現の調節
CA2993275C (en) 2015-08-20 2022-06-21 Aseko, Inc. Diabetes management therapy advisor
US10385017B2 (en) 2015-10-14 2019-08-20 Cadila Healthcare Limited Pyrrole compound, compositions and process for preparation thereof
WO2017089979A1 (en) 2015-11-26 2017-06-01 Cadila Healthcare Limited Dual ppar modulators for the treatment of diabetic nephropathy and related diseases
WO2017089980A1 (en) 2015-11-26 2017-06-01 Cadila Healthcare Limited Dual ppar modulators for the treatment of diabetic retinopathy and diabetic eye diseases
US20180243263A1 (en) 2016-12-09 2018-08-30 Cadila Healthcare Ltd. Treatment for primary biliary cholangitis
US20220071954A1 (en) 2018-12-18 2022-03-10 Cadila Healthcare Limited Saroglitazar for the treatment of hepatocellular carcinoma

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
MX7065E (es) 1980-06-06 1987-04-10 Sankyo Co Un procedimiento microbiologico para preparar derivados de ml-236b
US5354772A (en) 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5089514A (en) 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
PL176885B1 (pl) 1992-07-03 1999-08-31 Smithkline Beecham Plc Kompozycja farmaceutyczna
GB9225386D0 (en) 1992-12-04 1993-01-27 Smithkline Beecham Plc Novel compounds
US5387613A (en) 1993-07-23 1995-02-07 Ribogene, Inc. Treatment of tachyarrhythmias of supraventricular origin
GB9326171D0 (en) 1993-12-22 1994-02-23 Smithkline Beecham Plc Novel compounds
WO1996004261A1 (en) 1994-07-29 1996-02-15 Smithkline Beecham Plc Benzoxazoles and pryridine derivatives useful in the treatment of the type ii diabetes
CA2219675C (en) 1995-04-28 2009-08-18 Daiichi Pharmaceutical Co., Ltd. Pentacyclic compound
GB9600464D0 (en) 1996-01-09 1996-03-13 Smithkline Beecham Plc Novel method
GB9606805D0 (en) 1996-03-30 1996-06-05 Glaxo Wellcome Inc Medicaments
EP0897467B1 (en) 1996-12-24 2003-06-25 Daewoo Motor Co., Ltd. An apparatus with an exhaust gas recirculation valve for an internal combustion engine
WO1999019313A1 (en) 1997-10-27 1999-04-22 Dr. Reddy's Research Foundation Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them
CN1280574A (zh) 1997-10-27 2001-01-17 雷迪研究基金会 新的杂环化合物及其在医药中的应用、它们的制备方法和含有它们的药物组合物
WO1999020614A1 (en) 1998-05-27 1999-04-29 Dr. Reddy's Research Foundation Bicyclic compounds, process for their preparation and pharmaceutical compositions containing them
AU1120599A (en) 1998-04-23 1999-03-08 Dr. Reddy's Research Foundation New heterocyclic compounds and their use in medicine, process for their reparation and pharmaceutical compositions containing them
JP2002527503A (ja) 1998-10-21 2002-08-27 ノボ ノルディスク アクティーゼルスカブ 新規化合物類、それらの調製及び使用
AU6325599A (en) 1998-10-21 2000-05-08 Dr. Reddy's Research Foundation New compounds, their preparation and use
WO2000023451A1 (en) 1998-10-21 2000-04-27 Novo Nordisk A/S New compounds, their preparation and use
CO5150173A1 (es) 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
EE05082B1 (et) 2000-01-19 2008-10-15 Cadila Healthcare Ltd. Pürroolirea ühend, selle valmistamine ja kasutamine lipiidi- ja kolesteroolitaset alandava ravimi valmistamiseks ning seda sisaldav farmatseutiline kompositsioon
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
AU2001286163A1 (en) 2000-09-22 2002-04-02 Dr. Reddy's Research Foundation An improved process for the preparation of 3-aryl-2-hydroxy propanoic acid derivatives
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
US6987123B2 (en) 2001-07-26 2006-01-17 Cadila Healthcare Limited Heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
WO2005031335A1 (ja) 2003-09-26 2005-04-07 Mitsubishi Rayon Co., Ltd. 電気泳動装置および電気泳動法並びにそれを用いた生体関連物質の検出方法
NZ549716A (en) 2004-03-15 2010-04-30 Takeda Pharmaceutical Pyrimidin-dione derivatives as dipeptidyl peptidase inhibitors
EP2018157A2 (en) * 2006-04-26 2009-01-28 Astron Research Limited Controlled release formulation comprising anti-epileptic drugs
CN102647982B (zh) 2009-11-26 2014-10-15 基恩菲特公司 使用1,3-二苯基丙-2-烯-1-酮衍生物治疗肝脏疾患
JP2013539790A (ja) 2010-10-12 2013-10-28 ザ ジョンズ ホプキンス ユニバーシティ メマンチンを含む鎮咳組成物
UA110813C2 (uk) 2011-01-31 2016-02-25 Каділа Хелткере Лімітед Лікування ліподистрофії
EP2988736A1 (en) 2013-04-22 2016-03-02 Cadila Healthcare Limited A novel composition for nonalcoholic fatty liver disease (nafld)
EP3004053B1 (en) 2013-05-30 2021-03-24 Cadila Healthcare Limited A process for preparation of pyrroles having hypolipidemic hypocholesteremic activities
TW201636015A (zh) 2013-07-05 2016-10-16 卡地拉保健有限公司 協同性組成物
IN2013MU02470A (es) 2013-07-25 2015-06-26 Cadila Healthcare Ltd
WO2015029066A1 (en) 2013-08-29 2015-03-05 Cadila Healthcare Limited Polymorphic form of pyrrole derivative and intermediate thereof
WO2015033357A2 (en) 2013-09-06 2015-03-12 Cadila Healthcare Limited An improved process for the preparation of pyrrole derivatives

Also Published As

Publication number Publication date
US10017470B2 (en) 2018-07-10
EP2670486B1 (en) 2016-04-06
JP2014504610A (ja) 2014-02-24
CN103354757A (zh) 2013-10-16
AU2012212992A1 (en) 2013-07-25
SMT201600129B (it) 2016-07-01
MY191100A (en) 2022-05-30
KR20160038073A (ko) 2016-04-06
IL227266B (en) 2019-10-31
CN107056671A (zh) 2017-08-18
PL2670486T3 (pl) 2016-08-31
IL262611A (en) 2018-12-31
IL227266A0 (en) 2013-09-30
EA025421B1 (ru) 2016-12-30
RS54735B1 (sr) 2016-10-31
ES2569248T3 (es) 2016-05-09
US20190100492A1 (en) 2019-04-04
AU2012212992B2 (en) 2015-11-26
UA110813C2 (uk) 2016-02-25
KR20130128451A (ko) 2013-11-26
ME02392B (me) 2016-09-20
KR101733414B1 (ko) 2017-05-10
KR101633720B1 (ko) 2016-06-27
AU2015249076A1 (en) 2015-11-12
WO2012104869A1 (en) 2012-08-09
CY1117564T1 (el) 2017-04-26
CO6781497A2 (es) 2013-10-31
JP5956664B2 (ja) 2016-07-27
CA2825456A1 (en) 2012-08-09
DK2670486T3 (en) 2016-05-17
CA2825456C (en) 2016-01-05
HUE027512T2 (en) 2016-10-28
NZ612804A (en) 2015-09-25
MX350611B (es) 2017-09-11
BR112013019352A2 (pt) 2020-07-14
SG191772A1 (en) 2013-08-30
US20170088514A1 (en) 2017-03-30
JP2016028069A (ja) 2016-02-25
HRP20160403T1 (hr) 2016-06-03
EP2670486A1 (en) 2013-12-11
KR20150100949A (ko) 2015-09-02
SI2670486T1 (sl) 2016-09-30
CL2013002166A1 (es) 2014-04-11
US20130338209A1 (en) 2013-12-19
AP2013006988A0 (en) 2013-07-31
AP3920A (en) 2016-12-02
EP3009136A1 (en) 2016-04-20
EA201391108A1 (ru) 2013-12-30
US9783495B2 (en) 2017-10-10

Similar Documents

Publication Publication Date Title
MY191100A (en) Treatment for lipodystrophy
PH12018502489A1 (en) Antiviral therapy
CY1119490T1 (el) Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων
MX2014002171A (es) Tratamientos de combinacion para hepatitis c.
PH12016501750A1 (en) Human plasma kallikrein inhibitors
PH12016502355B1 (en) Pharmaceutical composition
EA201590371A1 (ru) 1,4-дизамещенные аналоги пиридазина и способы лечения связанных с дефицитом smn состояний
NZ735575A (en) Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
NZ732391A (en) Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
NZ704266A (en) Inhibitors of alpha-crystallin aggregation for the treatment for cataract
BR112012016673A2 (pt) método de tratamento.
MX2013008340A (es) Novedosas 4-amino-n-hidroxi-benzamidas para el tratamiento de cancer.
EA201690327A1 (ru) Терапевтические способы
BR112017002449A2 (pt) tratamento de sintomas associados com terapia de privação androgênica
MX2014011520A (es) Administracion de eritoran o sales farmaceuticamente aceptables del mismo para tratar infecciones para ortomixovirus.
UA79040U (ru) Способ лечения ВИЧ-инфекции

Legal Events

Date Code Title Description
FG Grant or registration